奥罗芬对 507 种丝状真菌(包括澳大利亚一家三级实验室的抗真菌药物耐药菌株)的体外活性:2020-2023 年。

IF 3.9 2区 医学 Q1 INFECTIOUS DISEASES Journal of Antimicrobial Chemotherapy Pub Date : 2024-10-01 DOI:10.1093/jac/dkae267
Catriona L Halliday, Enoch Tay, Wendy Green, Derek Law, Ronald Lopez, Silvia Faris, Lauren Meehan, Emma Harvey, Mike Birch, Sharon C A Chen
{"title":"奥罗芬对 507 种丝状真菌(包括澳大利亚一家三级实验室的抗真菌药物耐药菌株)的体外活性:2020-2023 年。","authors":"Catriona L Halliday, Enoch Tay, Wendy Green, Derek Law, Ronald Lopez, Silvia Faris, Lauren Meehan, Emma Harvey, Mike Birch, Sharon C A Chen","doi":"10.1093/jac/dkae267","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>New antifungal agents are required to mitigate against azole-resistant Aspergillus and drug-resistant non-Aspergillus moulds. The novel orotomide, olorofim (F2G, Manchester, UK), has potent fungicidal activity against Aspergillus including azole-resistant Aspergillus fumigatus, Lomentospora prolificans and Scedosporium spp. Development of olorofim-specific clinical breakpoints/epidemiological cut-off values requires reliable MIC data.</p><p><strong>Objectives: </strong>Determine the in vitro activity of olorofim compared with standard antifungals against mould pathogens at an Australian hospital.</p><p><strong>Materials and methods: </strong>Olorofim MICs were determined for 507 clinical mould isolates using the CLSI M38-A3 standard. MICs of amphotericin B, anidulafungin, posaconazole, voriconazole and isavuconazole were obtained using Sensititre™ YeastOne YO10 and AUSNMRCI panels (Thermo-Fisher Scientific).</p><p><strong>Results: </strong>A. fumigatus sensu stricto was the commonest species (33.3%) followed by L. prolificans (18.3%), Scedosporium (11.4%) and Fusarium (6%) species. Olorofim modal MICs were ≤0.25 mg/L (MIC90 0.25 mg/L) for all Aspergillus except Aspergillus Section Usti (1 mg/L); MICs for nine azole-resistant/non-wild-type A. fumigatus ranged from 0.008 to 0.125 mg/L. The MIC90 of olorofim for L. prolificans was 0.5 mg/L, 0.25-0.5 mg/L for Scedosporium spp. and 8 mg/L for the F. solani complex but with modal MICs of 0.25 and 0.008 mg/L for F. oxysporum and F. proliferatum complexes, respectively. For Verruconis gallopava (n = 10), the olorofim MIC90 was 0.06 mg/L (voriconazole MIC90 2 mg/L, isavuconazole MICs of 4->8 mg/L). Olorofim had little activity against other dematiaceous moulds including Exophiala species.</p><p><strong>Conclusions: </strong>Olorofim was highly active against Aspergillus spp. including azole-resistant A. fumigatus, L. prolificans, Scedosporium spp. and some Fusarium species with the new finding of potent activity against V. gallopava.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"In vitro activity of olorofim against 507 filamentous fungi including antifungal drug-resistant strains at a tertiary laboratory in Australia: 2020-2023.\",\"authors\":\"Catriona L Halliday, Enoch Tay, Wendy Green, Derek Law, Ronald Lopez, Silvia Faris, Lauren Meehan, Emma Harvey, Mike Birch, Sharon C A Chen\",\"doi\":\"10.1093/jac/dkae267\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>New antifungal agents are required to mitigate against azole-resistant Aspergillus and drug-resistant non-Aspergillus moulds. The novel orotomide, olorofim (F2G, Manchester, UK), has potent fungicidal activity against Aspergillus including azole-resistant Aspergillus fumigatus, Lomentospora prolificans and Scedosporium spp. Development of olorofim-specific clinical breakpoints/epidemiological cut-off values requires reliable MIC data.</p><p><strong>Objectives: </strong>Determine the in vitro activity of olorofim compared with standard antifungals against mould pathogens at an Australian hospital.</p><p><strong>Materials and methods: </strong>Olorofim MICs were determined for 507 clinical mould isolates using the CLSI M38-A3 standard. MICs of amphotericin B, anidulafungin, posaconazole, voriconazole and isavuconazole were obtained using Sensititre™ YeastOne YO10 and AUSNMRCI panels (Thermo-Fisher Scientific).</p><p><strong>Results: </strong>A. fumigatus sensu stricto was the commonest species (33.3%) followed by L. prolificans (18.3%), Scedosporium (11.4%) and Fusarium (6%) species. Olorofim modal MICs were ≤0.25 mg/L (MIC90 0.25 mg/L) for all Aspergillus except Aspergillus Section Usti (1 mg/L); MICs for nine azole-resistant/non-wild-type A. fumigatus ranged from 0.008 to 0.125 mg/L. The MIC90 of olorofim for L. prolificans was 0.5 mg/L, 0.25-0.5 mg/L for Scedosporium spp. and 8 mg/L for the F. solani complex but with modal MICs of 0.25 and 0.008 mg/L for F. oxysporum and F. proliferatum complexes, respectively. For Verruconis gallopava (n = 10), the olorofim MIC90 was 0.06 mg/L (voriconazole MIC90 2 mg/L, isavuconazole MICs of 4->8 mg/L). Olorofim had little activity against other dematiaceous moulds including Exophiala species.</p><p><strong>Conclusions: </strong>Olorofim was highly active against Aspergillus spp. including azole-resistant A. fumigatus, L. prolificans, Scedosporium spp. and some Fusarium species with the new finding of potent activity against V. gallopava.</p>\",\"PeriodicalId\":14969,\"journal\":{\"name\":\"Journal of Antimicrobial Chemotherapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Antimicrobial Chemotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/jac/dkae267\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Antimicrobial Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jac/dkae267","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:需要新的抗真菌剂来减轻对唑类耐药曲霉菌和非曲霉菌的耐药性。新型奥罗托咪唑--奥罗非姆(F2G,英国曼彻斯特)对曲霉菌(包括耐唑曲霉菌、多孔菌和头孢菌属)具有很强的杀真菌活性,但开发奥罗非姆特异性临床断点/流行病学临界值需要可靠的 MIC 数据:在澳大利亚的一家医院中,与标准抗真菌药相比,确定奥罗芬对霉菌病原体的体外活性:采用 CLSI M38-A3 标准测定了 507 个临床霉菌分离株的奥罗芬 MIC。使用 Sensititre™ YeastOne YO10 和 AUSNMRCI 面板(Thermo-Fisher Scientific)测定两性霉素 B、阿尼妥芬、泊沙康唑、伏立康唑和异武康唑的 MIC:结果:严格意义上的烟曲霉是最常见的菌种(33.3%),其次是增殖酵母菌(18.3%)、Scedosporium(11.4%)和镰刀菌(6%)。除乌斯季曲霉(1 毫克/升)外,奥罗芬对所有曲霉的 MIC 值均小于 0.25 毫克/升(MIC90 为 0.25 毫克/升);对 9 种抗唑/非野生型烟曲霉的 MIC 值介于 0.008 至 0.125 毫克/升之间。Olorofim 对 L. prolificans 的 MIC90 为 0.5 毫克/升,对 Scedosporium 属的 MIC90 为 0.25-0.5 毫克/升,对 F. solani 复合物的 MIC90 为 8 毫克/升,但对 F. oxysporum 和 F. proliferatum 复合物的模式 MIC 分别为 0.25 和 0.008 毫克/升。对于 Verruconis gallopava(n = 10),Olorofim 的 MIC90 为 0.06 mg/L(伏立康唑的 MIC90 为 2 mg/L,异戊唑的 MIC 为 4->8 mg/L)。Olorofim 对包括 Exophiala 菌在内的其他脱霉菌几乎没有活性:结论:Olorofim 对曲霉菌属(包括耐唑曲霉菌属)、L. prolificans、Scedosporium 菌属和一些镰刀菌属具有很高的活性,对 V. gallopava 菌属也有很强的活性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
In vitro activity of olorofim against 507 filamentous fungi including antifungal drug-resistant strains at a tertiary laboratory in Australia: 2020-2023.

Background: New antifungal agents are required to mitigate against azole-resistant Aspergillus and drug-resistant non-Aspergillus moulds. The novel orotomide, olorofim (F2G, Manchester, UK), has potent fungicidal activity against Aspergillus including azole-resistant Aspergillus fumigatus, Lomentospora prolificans and Scedosporium spp. Development of olorofim-specific clinical breakpoints/epidemiological cut-off values requires reliable MIC data.

Objectives: Determine the in vitro activity of olorofim compared with standard antifungals against mould pathogens at an Australian hospital.

Materials and methods: Olorofim MICs were determined for 507 clinical mould isolates using the CLSI M38-A3 standard. MICs of amphotericin B, anidulafungin, posaconazole, voriconazole and isavuconazole were obtained using Sensititre™ YeastOne YO10 and AUSNMRCI panels (Thermo-Fisher Scientific).

Results: A. fumigatus sensu stricto was the commonest species (33.3%) followed by L. prolificans (18.3%), Scedosporium (11.4%) and Fusarium (6%) species. Olorofim modal MICs were ≤0.25 mg/L (MIC90 0.25 mg/L) for all Aspergillus except Aspergillus Section Usti (1 mg/L); MICs for nine azole-resistant/non-wild-type A. fumigatus ranged from 0.008 to 0.125 mg/L. The MIC90 of olorofim for L. prolificans was 0.5 mg/L, 0.25-0.5 mg/L for Scedosporium spp. and 8 mg/L for the F. solani complex but with modal MICs of 0.25 and 0.008 mg/L for F. oxysporum and F. proliferatum complexes, respectively. For Verruconis gallopava (n = 10), the olorofim MIC90 was 0.06 mg/L (voriconazole MIC90 2 mg/L, isavuconazole MICs of 4->8 mg/L). Olorofim had little activity against other dematiaceous moulds including Exophiala species.

Conclusions: Olorofim was highly active against Aspergillus spp. including azole-resistant A. fumigatus, L. prolificans, Scedosporium spp. and some Fusarium species with the new finding of potent activity against V. gallopava.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
9.20
自引率
5.80%
发文量
423
审稿时长
2-4 weeks
期刊介绍: The Journal publishes articles that further knowledge and advance the science and application of antimicrobial chemotherapy with antibiotics and antifungal, antiviral and antiprotozoal agents. The Journal publishes primarily in human medicine, and articles in veterinary medicine likely to have an impact on global health.
期刊最新文献
Emergence of the mobile RND-type efflux pump gene cluster tmexCD1-toprJ1 in Klebsiella pneumoniae clinical isolates in Japan. Rapid viral suppression using integrase inhibitors during acute HIV-1 infection. Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol? Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial. Oral antimicrobial agents in patients with short bowel syndrome: worth a try!-authors' response.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1